EULAR rheumatology open · 2026
The epidemiology of inflammatory rheumatic diseases in Germany in a European context: a systematic review to support workforce planning.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Albrecht Katinka, Veltri Carlo A G, Strangfeld Anja, Callhoff Johanna
Аннотация
OBJECTIVES: The number of adults living with inflammatory rheumatic diseases (iRMDs) in a country is key for calculating the demand for rheumatologists. Our aim was to estimate the incidence and prevalence of iRMD in Germany by compiling current epidemiologic German and other European data.
METHODS: A systematic review included original studies on prevalence and incidence of iRMDs in Germany and other European countries, covering study data from 2013 to the present. Considering heterogeneous methodology, we qualitatively estimated the prevalence and incidence for 11 iRMDs and extrapolated the results to the German population.
RESULTS: A total of 20 German and 72 studies from other European countries were considered. All German studies used claims data with moderate to high risk of bias. Studies relying solely on International Classification of Diseases codes as case definition reported higher rates than those applying diagnostic criteria or multistage population-based methods. Prevalence ranges (with estimates for Germany in parentheses) per 100,000 are: rheumatoid arthritis 410 to 1380 (1000), polymyalgia rheumatica 100 to 937 (600 aged >50 years), axial spondyloarthritis 75 to 500 (300), psoriatic arthritis 20 to 580 (300), giant cell arteritis 76 to 250 (146 aged >50 years), primary Sjögren's disease 32 to 250 (70), systemic lupus erythematosus 35 to 210 (56), systemic sclerosis 17 to 50 (35), idiopathic inflammatory myopathies 17 to 25 (17), anti-neutrophil cytoplasmic antibody-associated vasculitides 14 to 43 (26), and Behçet's disease 0.3 to 15 (4.7). Overall, we estimate the prevalence of iRMD in Germany to be 2.6% (1.8 million adults) and an annual incidence of 0.2% (130,000 adults).
CONCLUSIONS: This study compiles European epidemiological data on 11 iRMDs to calculate the number of people affected. The methodology could be a blueprint for studies in other regions.
METHODS: A systematic review included original studies on prevalence and incidence of iRMDs in Germany and other European countries, covering study data from 2013 to the present. Considering heterogeneous methodology, we qualitatively estimated the prevalence and incidence for 11 iRMDs and extrapolated the results to the German population.
RESULTS: A total of 20 German and 72 studies from other European countries were considered. All German studies used claims data with moderate to high risk of bias. Studies relying solely on International Classification of Diseases codes as case definition reported higher rates than those applying diagnostic criteria or multistage population-based methods. Prevalence ranges (with estimates for Germany in parentheses) per 100,000 are: rheumatoid arthritis 410 to 1380 (1000), polymyalgia rheumatica 100 to 937 (600 aged >50 years), axial spondyloarthritis 75 to 500 (300), psoriatic arthritis 20 to 580 (300), giant cell arteritis 76 to 250 (146 aged >50 years), primary Sjögren's disease 32 to 250 (70), systemic lupus erythematosus 35 to 210 (56), systemic sclerosis 17 to 50 (35), idiopathic inflammatory myopathies 17 to 25 (17), anti-neutrophil cytoplasmic antibody-associated vasculitides 14 to 43 (26), and Behçet's disease 0.3 to 15 (4.7). Overall, we estimate the prevalence of iRMD in Germany to be 2.6% (1.8 million adults) and an annual incidence of 0.2% (130,000 adults).
CONCLUSIONS: This study compiles European epidemiological data on 11 iRMDs to calculate the number of people affected. The methodology could be a blueprint for studies in other regions.